Skip to content

Clinical trials

Phase 2 Central Nervous System Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Central Nervous System Neoplasms Phase: Phase 2 Clear all

209 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200016
200113
200213
200310
20049
200511
200611
20079
20085
20099
20103
20114
20121
20132
20151
201711
20182
20191
20201
20212
20223
20241
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed149
Unknown status22
Terminated16
Active, not recruiting8
Withdrawn7
Recruiting6
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)18
Duke University14
European Organisation for Research and Treatment of Cancer - EORTC12
Children's Oncology Group11
Memorial Sloan Kettering Cancer Center11
Children's Cancer and Leukaemia Group10
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins10
Dana-Farber Cancer Institute7
Radiation Therapy Oncology Group7
Jonsson Comprehensive Cancer Center6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Central Nervous System Neoplasms209
Glioblastoma90
Brain Neoplasms87
Gliosarcoma81
Astrocytoma72
Glioma55
Oligodendroglioma52
Medulloblastoma31
Ependymoma25
Neuroblastoma23

Trials

Showing 1 to 25 of 209. Each trial links to its page on Pharma Observatory.

109 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.